Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel

References

• Valgimigli M, Bueno H, Byrne RA, Collet J, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2018;53:34–78. doi:https://doi.org/10.1093/ejcts/ezx334.
   PubMed Web of Science ®Google Scholar
• Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016;388:2015–2022. doi:https://doi.org/10.1016/S0140-6736(16)31323-X.
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, Lambert M, Juhan-Vague I, Bonnet J-L, Alessi M-C, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007;98:838–843. doi:https://doi.org/10.1160/TH07-04-0296.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the prepare post-stenting study. J Am Coll Cardiol 2005;46(10):1820–1826. doi:https://doi.org/10.1016/j.jacc.2005.07.041.
   PubMed Web of Science ®Google Scholar
• Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, Ten Berg J, Janssen P, Angiolillo DJ, et al. Bleeding and stent thrombosis on P2Y 12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015;36:1762–1771. doi:https://doi.org/10.1093/eurheartj/ehv104.
   PubMed Web of Science ®Google Scholar
• Wang Z, Xie Q, Xiang Q, Gong Y, Jiang J, Cui Y. Predictive Value of Methods Measuring Platelet Activation for Ischemic Events in Patients Receiving Clopidogrel: A Systematic Review and Meta-analysis. Curr Pharm Des 2018;24:5313–5333. doi:https://doi.org/10.2174/1381612825666190206114724.
   PubMed Web of Science ®Google Scholar
• Guan J, Cong Y, Ren J, Zhu Y, Li L, Deng X, Bai J. Comparison between a new platelet count drop method PL-11, light transmission aggregometry, verify now aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals. Platelets 2015;26:25–30. doi:https://doi.org/10.3109/09537104.2013.865835.
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847. doi:https://doi.org/10.1161/01.CIR.97.18.1837.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao Y, Ji S, Zhao Y, Jiang M, Jin X, Shi J-F, Gu G-H, Ruan C-G. Evaluation of a new method and instrument for detection platelet aggregation function and its clinical application. J Exp Hematol 2013;21:674–677. doi:https://doi.org/10.7534/j..1009-2137.2013.03.027.
   Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, .et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754–762. doi:https://doi.org/10.1001/jama.2010.181.
   PubMed Web of Science ®Google Scholar
• Salvemini D, de Nucci G, Gryglewski RJ, Vane JR. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A 1989;86:6328–6332. doi:https://doi.org/10.1073/pnas.86.16.6328.
   PubMed Web of Science ®Google Scholar
• Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312–2317. doi:https://doi.org/10.1016/j.jacc.2007.01.094.
   PubMed Web of Science ®Google Scholar
• Gao X, Lu S, Ge Z, Zuo G, Wang Z, Wang F, Kong X-Q, Chai D-Y, Chen S-L, Zhang -J-J, et al. Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study. BMC Cardiovasc Disord 2018;18:103. doi:https://doi.org/10.1186/s12872-018-0841-1.
   PubMed Web of Science ®Google Scholar
• Collet J, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100–2109. doi:https://doi.org/10.1056/NEJMoa1209979.
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay J, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–1105. doi:https://doi.org/10.1001/jama.2011.290.
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–857. doi:https://doi.org/10.1001/jama.2009.1232.
   PubMed Web of Science ®Google Scholar
• Li X, Wang Z, Wang Q, Xu Q, Lv Q. Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients. Basic Clin Pharmacol Toxicol 2019;124:84–93. doi:https://doi.org/10.1111/bcpt.13110.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD. Cytochrome P-450 polymorphisms and response to clopidogrel. J Vasc Surg 2009;49:1083. doi:https://doi.org/10.1016/j.jvs.2009.02.023.
   Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363–375. doi:https://doi.org/10.1056/NEJMoa0808227.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet J, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 2010;304:1821. doi:https://doi.org/10.1001/jama.2010.1543.
   PubMed Web of Science ®Google Scholar
• Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis J-F, O’Brien E, Goncalves S, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012;379:1705–1711. doi:https://doi.org/10.1016/S0140-6736(12)60161-5.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, et al. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. J Cardiol 2016;68:29–36. doi:https://doi.org/10.1016/j.jjcc.2015.07.019.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang L, Wang H, Li S, Zhang Y, You L, Sun Y, Wang D, Yang J, Cui Y, et al. Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention — a multicenter study. Int J Cardiol 2017;240:360–366. doi:https://doi.org/10.1016/j.ijcard.2017.03.015.
   PubMed Web of Science ®Google Scholar
• Collet J, Kerneis M, Hulot J, O’Connor SA, Silvain J, Mansencal N, Brugier D, Abtan J, Barthélémy O, Vignalou J-B, et al. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. Thromb Haemost 2016;115:382. doi:https://doi.org/10.1160/th15-05-0394.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn H, Büttner HJ, Neumann F-J. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55(22):2427–2434. doi:https://doi.org/10.1016/j.jacc.2010.02.031.
   PubMed Web of Science ®Google Scholar